These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19581601)

  • 1. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.
    Britschgi M; Olin CE; Johns HT; Takeda-Uchimura Y; LeMieux MC; Rufibach K; Rajadas J; Zhang H; Tomooka B; Robinson WH; Clark CM; Fagan AM; Galasko DR; Holtzman DM; Jutel M; Kaye JA; Lemere CA; Leszek J; Li G; Peskind ER; Quinn JF; Yesavage JA; Ghiso JA; Wyss-Coray T
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12145-50. PubMed ID: 19581601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques.
    Hoogerhout P; Kamphuis W; Brugghe HF; Sluijs JA; Timmermans HA; Westdijk J; Zomer G; Boog CJ; Hol EM; van den Dobbelsteen GP
    PLoS One; 2011 Apr; 6(4):e19110. PubMed ID: 21526148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A conformation-specific antibody against oligomeric β-amyloid restores neuronal integrity in a mouse model of Alzheimer's disease.
    He P; Schulz P; Sierks MR
    J Biol Chem; 2021; 296():100241. PubMed ID: 33376140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of conformation- and sequence-specific antibodies against amyloid β.
    Perchiacca JM; Ladiwala AR; Bhattacharya M; Tessier PM
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):84-9. PubMed ID: 22171009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.
    Mruthinti S; Buccafusco JJ; Hill WD; Waller JL; Jackson TW; Zamrini EY; Schade RF
    Neurobiol Aging; 2004 Sep; 25(8):1023-32. PubMed ID: 15212827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
    Du Y; Dodel R; Hampel H; Buerger K; Lin S; Eastwood B; Bales K; Gao F; Moeller HJ; Oertel W; Farlow M; Paul S
    Neurology; 2001 Sep; 57(5):801-5. PubMed ID: 11552007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
    Lambert MP; Viola KL; Chromy BA; Chang L; Morgan TE; Yu J; Venton DL; Krafft GA; Finch CE; Klein WL
    J Neurochem; 2001 Nov; 79(3):595-605. PubMed ID: 11701763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits.
    Acero G; Manoutcharian K; Vasilevko V; Munguia ME; Govezensky T; Coronas G; Luz-Madrigal A; Cribbs DH; Gevorkian G
    J Neuroimmunol; 2009 Aug; 213(1-2):39-46. PubMed ID: 19545911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
    Moretto N; Bolchi A; Rivetti C; Imbimbo BP; Villetti G; Pietrini V; Polonelli L; Del Signore S; Smith KM; Ferrante RJ; Ottonello S
    J Biol Chem; 2007 Apr; 282(15):11436-45. PubMed ID: 17267402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
    Kim HD; Jin JJ; Maxwell JA; Fukuchi K
    Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.
    Söllvander S; Ekholm-Pettersson F; Brundin RM; Westman G; Kilander L; Paulie S; Lannfelt L; Sehlin D
    J Alzheimers Dis; 2015; 48(1):63-72. PubMed ID: 26401929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.
    De Felice FG; Vieira MN; Saraiva LM; Figueroa-Villar JD; Garcia-Abreu J; Liu R; Chang L; Klein WL; Ferreira ST
    FASEB J; 2004 Sep; 18(12):1366-72. PubMed ID: 15333579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
    Venkataramani V; Wirths O; Budka H; Härtig W; Kovacs GG; Bayer TA
    J Alzheimers Dis; 2012; 29(2):361-71. PubMed ID: 22232007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.
    Moir RD; Tseitlin KA; Soscia S; Hyman BT; Irizarry MC; Tanzi RE
    J Biol Chem; 2005 Apr; 280(17):17458-63. PubMed ID: 15728175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-amyloidogenic activity of IgGs contained in normal plasma.
    O'Nuallain B; Williams AD; McWilliams-Koeppen HP; Acero L; Weber A; Ehrlich H; Schwarz HP; Solomon A
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S37-42. PubMed ID: 20405179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.